Skip Navigation


Rheumatology Advance Access originally published online on August 20, 2009
Rheumatology 2009 48(10):1218-1221; doi:10.1093/rheumatology/kep215
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/10/1218    most recent
kep215v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nihtyanova, S. I.
Right arrow Articles by Denton, C. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nihtyanova, S. I.
Right arrow Articles by Denton, C. P.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis

Svetlana I. Nihtyanova1, Jennifer C. Parker2, Carol M. Black1, Christopher C. Bunn2 and Christopher P. Denton1

1Centre for Rheumatology and Connective Tissue Diseases and 2Clinical Immunology Department, Royal Free Hospital, London, UK.

Correspondence to: Christopher P. Denton, Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital, Pond Street, London NW3 2QG, UK. E-mail: c.denton{at}medsch.ucl.ac.uk


  Abstract

Objectives. Anti-RNA-polymerase antibodies (ARAs) are associated with the diffuse cutaneous subset of SSc (dcSSc) and particularly with scleroderma renal crisis (SRC). We analysed serial ARA levels and explored the relationship with clinical features and disease outcome.

Methods. A commercially available ELISA method with a recombinant peptide of RNA polymerase III was used and ARA levels were measured in a well-characterized cohort of SSc cases.

Results. ARA levels were measured in 64 SSc patients. Of them, 78% (n = 50) were females and 92% (n = 59) had dcSSc, 39% (n = 25) had SRC, 20% (n = 13) had pulmonary fibrosis (PF), 9% (n = 6) had pulmonary arterial hypertension and 3% (n = 2) had cardiac involvement. There was considerable inter- and intra-patient variability in ARA levels (11–210 U/ml). There was no correlation between absolute ARA levels (at baseline or throughout the disease course) and outcome. There was a moderate correlation between time to peak ARA level and development of significant PF (Pearson correlation = 0.669, P = 0.034), but no correlation between peak ARA levels and onset of SRC. ARA levels change correlated with change in skin score (correlation coefficient within subjects = 0.236, P = 0.011).

Conclusions. The pathogenic significance of ARA is unclear. Despite the very strong association of ARA with SRC, we could not show the clinically significant association between absolute levels of antibody and development of internal organ complications, which makes repeated measurements of ARA levels unnecessary. However, changes in ARA level over time occur and may reflect changes in skin score.

KEY WORDS: Systemic sclerosis, Scleroderma renal crisis, Anti-RNA polymerase antibody, Antibodies

Submitted 27 February 2009; revised version accepted 22 June 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.